Browsing eNauka
Browsing by Author Secen, Nevena M
Showing results 1 to 15 of 15
| Issue Date | Title | Author(s) | Type | М-cat. |
|---|---|---|---|---|
| 2013 | Analysis of clinicopathological characteristics of 982 lung cancer patients and subsequent treatment Epidemiology study | Jovanovic, Dragana D; Secen, Nevena M; Murtezani, Zafir; Rancic, Milan H   ; Kacar-Kukric, Vesna D; Velinovic, Marta; Tepavac, Ana; Budisin, Evica S; Andric, Zoran G ; Vukobradovic-Djoric, Nevena | Conference Paper | Mp. category will be shown later |
| 2008 | Aprepitant - where do we stand in the control of chemotherapy-induced nausea and vomiting? | Sarcev, Tatjana; Secen, Nevena M; Zaric, Bojan ; Milovancev, Aleksandar | Article | Mp. category will be shown later |
| 2010 | Atelectasis: positive or negative prognostic factor on outcome of patients with non-small cell lung cancer? | Tepavac, Aleksandar; Secen, Nevena M; Sazdanic-Velikic, Danica S; Popovic, G; Perin, Branislav M | Article | 23M23 |
| 2019 | Can Prophylactic Cranial Irradiation Reduce Neurological Symptoms in Patients with Small Cell Lung Cancer? | Boskovic, Tatjana V; Secen, Nevena M; Vitorovic, Sonja; Sevo, Milica; Culibrk, Tamara; Bokan, Darijo | Conference Paper | Mp. category will be shown later |
| 2012 | Characteristics of 982 Lung Cancer Patients in Serbia According to the Who/Iaslc Classification of Lung Cancers and Subsequent Treatment Avatar Epidemiology Study | Jovanovic, Dusan; Secen, Nevena M; Murtezani, Zafir; Rancic, Milan H ; Kacar-Kukric, Vesna D; Velinovic, Milos M; Tepavac, Aleksandar; Budisin, Evica S; Andric, Zoran G ; Vukobradovic-Djoric, Nevena | Conference Paper | Mp. category will be shown later |
| 2014 | Defense Mechanisms of the Respiratory System and Aerosol Production Systems | Zarogoulidis, Paul; Darwiche, Kaid; Yarmus, Lonny; Spyratos, Dionysios; Secen, Nevena M; Hohenforst-Schmidt, Wolfgang; Katsikogiannis, Nikolaos; Huang, Haidong; Gschwendtner, Andreas; Zarogoulidis, Konstantinos | Article | 23M23 |
| 2021 | EPROPA: The European program for routine testing of patients with advanced lung cancer | Passiglia, F; ...; Secen, Nevena M; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2014 | Paraneoplastic dermatomyositis associated with adenocarcinoma of the lung | Bursac, Daliborka S; Sazdanic-Velikic, Danica S; Tepavac, Aleksandar; Secen, Nevena M | Article | 23M23 |
| 2020 | Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). | Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2020 | Randomized, double-blind, phase II study of tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected NSCLC (CITYSCAPE) | Rodriguez-Abreu, Delvys; ...; Secen, Nevena M; ...; (broj, koautora 21) | Conference Paper | Mp. category will be shown later |
| 2012 | Survival of patients with severe chronic obstructive pulmonary disease in relation to smoking habits | Tot-Veres, Kristina; Secen, Nevena M; Povazan, Djordje; Zvekic-Svorcan, Jelena S | Conference Paper | Mp. category will be shown later |
| 2022 | The European Program for ROutine Testing of Patients with Advanced Lung Cancer (EPROPA) 1 Year Activity | Passiglia, F; ...; Secen, Nevena M; ...; (broj, koautora 25) | Conference Paper | Mp. category will be shown later |
| 2017 | The Prognostic Significance of Thrombocytopenia during Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer | Tepavac, Aleksandar; Sazdanic-Velikic, Danica S; Bursac, Daliborka S; Sarcev, Tatjana; Secen, Nevena M | Conference Paper | Mp. category will be shown later |
| 2022 | Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study | Cho, Byoung Chul; ...; Secen, Nevena M; ...; (broj, koautora 19) | Article | 21aM21a |
| 2021 | Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab plus atezolizumab (TA) versus placebo plus atezolizumab (PA) as first-line treatment for PD-L1+NSCLC | Cho, BC; ...; Secen, Nevena M; ...; (broj, koautora 19) | Conference Paper | Mp. category will be shown later |